4-Pro-MET vs 4-AcO-DMT: Cross-Substance Comparison

Both are ester prodrugs of 4-hydroxy tryptamines. But they convert to different active metabolites – and that changes the experience in ways that matter. 4-Pro-MET yields 4-HO-MET (metocin, N-methyl-N-ethyl); 4-AcO-DMT yields psilocin/4-HO-DMT (N,N-dimethyl). This comparison breaks down how the N-substitution pattern difference plays out in practice, along with the ester chemistry distinction (propionyloxy vs acetyloxy).

The core pharmacological distinction sits at the nitrogen. 4-HO-MET carries asymmetric N-methyl-N-ethyl groups; psilocin has symmetric N,N-dimethyl groups. One structural difference. Measurably different receptor binding dynamics. Consistently different subjective reports.

MET-series metabolites (like 4-HO-MET) reliably produce what users call a "clearer headspace" – ego function stays more intact, social interaction feels easier, and the whole experience runs lighter and more playful. DMT-series metabolites (like psilocin) pull in a different direction: deeper introspection, stronger ego dissolution at equivalent doses, more emotionally intense sessions. Both produce visuals, but the character splits. MET-series: sharp geometric patterns with "artificial" color saturation. DMT-series: organic and flowing.

The ester groups add another layer. 4-Pro-MET's propionyloxy (C3) ester is one carbon longer than 4-AcO-DMT's acetyloxy (C2) ester. That affects onset: the longer propionyloxy ester hydrolyzes more slowly, likely contributing to 4-Pro-MET's reported 20-60 minute onset versus 4-AcO-DMT's 20-40 minutes. And the propionyloxy group provides marginally better storage stability through increased steric protection of the ester bond.

Then there's the legal picture. 4-AcO-DMT was added to BtMG Anlage I in Germany in 2022. 4-Pro-MET remains unscheduled as of April 2026. So researchers choosing between these compounds need to weigh both the experiential profile difference and the legal landscape.